Vorinostat Completed Phase 2 Trials for Recurrent Non-Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00703664Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma